 SAN DIEGO, Jan. 05, 2021 GLOBE NEWSWIRE -- Histogen Inc. Nasdaq: HSTO, a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the bodys natural process to repair and maintain healthy biological function, today announced that it has closed its previously announced public offering of 11,600,000 shares of common stock, pre-funded warrants to purchase up to 2,400,000 shares of common stock and warrants to purchase up to an aggregate of 14,000,000 shares of common stock. The combined purchase price of one share of common stock and accompanying warrant was 1.00, and the combined purchase price of one pre-funded warrant and accompanying common warrant was 0.9999. Each share of common stock or common stock equivalent offered through the issuance of a pre-funded warrant was sold in the offering with one warrant to purchase one share of common stock. The common warrants have an exercise price of 1.00 per share, are immediately exercisable, and expire five years following the date of issuance. The pre-funded warrants have an exercise price of 0.0001 per share and are immediately exercisable. 